CLIA Kit for Vascular Endothelial Growth Factor Receptor 1 (VEGFR1)
Flt1; Fms-Related Tyrosine Kinase 1; Vascular Permeability Factor Receptor; Fms-like tyrosine kinase 1; Tyrosine-protein kinase receptor FLT
- UOM
- FOB US$ 588.00 US$ 840.00 US$ 3,780.00 US$ 7,140.00 US$ 58,800.00
- Quantity
Overview
Properties
- Product No.SCB818Hu
- Organism SpeciesHomo sapiens (Human) Same name, Different species.
- ApplicationsChemiluminescent immunoassay for Antigen Detection.
Research use only - DownloadInstruction Manual
- CategorySignal transductionTumor immunity
Sign into your account
Share a new citation as an author
Upload your experimental result
Review

Contact us
Please fill in the blank.
Recovery
Matrices listed below were spiked with certain level of recombinant Vascular Endothelial Growth Factor Receptor 1 (VEGFR1) and the recovery rates were calculated by comparing the measured value to the expected amount of Vascular Endothelial Growth Factor Receptor 1 (VEGFR1) in samples.
Matrix | Recovery range (%) | Average(%) |
serum(n=5) | 79-104 | 87 |
EDTA plasma(n=5) | 93-104 | 101 |
heparin plasma(n=5) | 85-98 | 90 |
Precision
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Vascular Endothelial Growth Factor Receptor 1 (VEGFR1) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Vascular Endothelial Growth Factor Receptor 1 (VEGFR1) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%
Linearity
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Vascular Endothelial Growth Factor Receptor 1 (VEGFR1) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
Sample | 1:2 | 1:4 | 1:8 | 1:16 |
serum(n=5) | 79-101% | 81-93% | 95-103% | 82-101% |
EDTA plasma(n=5) | 98-105% | 99-105% | 81-93% | 94-105% |
heparin plasma(n=5) | 84-101% | 78-99% | 82-98% | 94-102% |
Stability
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Reagents and materials provided
Reagents | Quantity | Reagents | Quantity |
Pre-coated, ready to use 96-well strip plate | 1 | Plate sealer for 96 wells | 4 |
Standard | 2 | Standard Diluent | 1×20mL |
Detection Reagent A | 1×120µL | Assay Diluent A | 1×12mL |
Detection Reagent B | 1×120µL | Assay Diluent B | 1×12mL |
Substrate A | 1×10mL | Substrate B | 1×2mL |
Wash Buffer (30 × concentrate) | 1×20mL | Instruction manual | 1 |
Assay procedure summary
1. Prepare all reagents, samples and standards;
2. Add 100µL standard or sample to each well. Incubate 1 hours at 37°C;
3. Aspirate and add 100µL prepared Detection Reagent A. Incubate 1 hour at 37°C;
4. Aspirate and wash 3 times;
5. Add 100µL prepared Detection Reagent B. Incubate 30 minutes at 37°C;
6. Aspirate and wash 5 times;
7. Add 100µL Substrate Solution. Incubate 10 minutes at 37°C;
8. Read RLU value immediately.

Test principle
The microplate provided in this kit has been pre-coated with an antibody specific to Vascular Endothelial Growth Factor Receptor 1 (VEGFR1). Standards or samples are then added to the appropriate microplate wells with a biotin-conjugated antibody specific to Vascular Endothelial Growth Factor Receptor 1 (VEGFR1). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. Then the mixture of substrate A and B is added to generate glow light emission kinetics. Upon plate development, the intensity of the emitted light is proportional to the Vascular Endothelial Growth Factor Receptor 1 (VEGFR1) level in the sample or standard.;
Giveaways
Increment services
-
Single-component Reagents of Assay Kit
-
Lysis Buffer Specific for ELISA / CLIA
-
Quality Control of Kit
-
CLIA Kit Customized Service
-
Disease Model Customized Service
-
Serums Customized Service
-
TGFB1 Activation Reagent
-
Real Time PCR Experimental Service
-
Streptavidin
-
Fast blue Protein Stain solution
-
Single-component Reagents of FLIA Kit
-
Streptavidin-Agarose Beads
Citations
- Growth Differentiation Factor 15 and Coronary Collateral FormationPubMed: 20014173
- Mutant hypoxia inducible factor-1α improves angiogenesis and tissue perfusion in ischemic rabbit skeletal muscle PubMed: 20937289
- Antiangiogenic Activities of Cinnamon, Black and Green Tea Extracts on Experimentally Induced Breast Cancer in RatsScialert: Source
- Antioxidant and bone repair properties of quercetin-functionalized hydroxyapatite: an in vitro osteoblast-osteoclast-endothelial cell co-culture studyPubMed: 26689470
- The multi-kinase inhibitor pazopanib targets hepatic stellate cell activation and apoptosis alleviating progression of liver fibrosisPubMed: 26269412
- Antioxidant and bone repair properties of quercetin-functionalized hydroxyapatite: An in vitro osteoblast–osteoclast–endothelial cell co-culture studyPubmed:26689470
- A Human 3D In Vitro Model to Assess the Relationship Between Osteoporosis and Disseminationto Bone of Breast Cancer Tumor Cells.pubmed:27925188
- Fasudil attenuates soluble fms-like tyrosine kinase-1 (sFlt-1)-induced hypertension in pregnant mice through RhoA/ROCK pathway.pubmed:29262624
- Modulating circulating sFlt1 in an animal model of preeclampsia using PAMAM nanoparticles for siRNA delivery.pubmed:28962687
- Synergistic effect of Si-hydroxyapatite coating and VEGF adsorption on Ti6Al4V-ELI scaffolds for bone regeneration in an osteoporotic bone environmentPubmed: 30445158
- Association between Upper-airway Surgery and Ameliorative Risk Markers of endothelial function in obstructive Sleep ApneaPubmed: 31882827
- Effect of isotretinoin (13-cis-retinoic acid) on levels of soluble VEGF receptors (sVEGFR1, sVEGFR2, sVEGFR3) in patients with acne vulgarisPubmed: 32043381
- Cyclin G2 upregulation impairs migration, invasion, and network formation through RNF123/Dvl2/JNK signaling in the trophoblast cell line HTR8/SVneo, a possible …Pubmed: 33205477
- sFlt-1/PlGF Ratio in Prediction of Short-Term Neonatal Outcome of Small for Gestational Age Neonates34438609
- Reactive Oxygen Species are Essential for Placental Angiogenesis During Early GestationPubmed:35693704